ClinicalTrials.gg
RecruitingNCT06708338FAVORIUpdated Aug 4, 2026

Impact of Bevel Orientation on Arteriovenous Fistula Puncture in Hemodialysis

An interventional study of Needle bevel orientation for arteriovenous fistula puncture in End-Stage Renal Disease Requiring Haemodialysis, sponsored by Centre Hospitalier Emile Roux. Recruiting at 4 sites in France. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-08-04.

Sponsored by Centre Hospitalier Emile Roux · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Arteriovenous Fistula with a site in France — 2 open to participants now, 4 under way, none of them phase 3. Arteriovenous Fistula · France.

Planned enrollment
2nd of 12
240 · median 60
Started
2026
the only one that year
No phase
11 of 21
1 open now
Registered
21st of 21
by date
Lead sponsor
1 of 21
Centre Hospitalier Emile Roux

Among the 21 studies in Arteriovenous Fistula with a site in France, this one is the 2nd largest by planned enrollment of the 12 interventional ones that give a count, is the only one that started in 2026, is one of 11 with no phase, and was the 21st registered.

Arteriovenous Fistula

248 studies on the registry are indexed under Arteriovenous Fistula; 44 are open to participants now.

Browse Arteriovenous Fistula studies →

Open to participants now

2 of the 21 studies in Arteriovenous Fistula with a site in France are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 27 Arteriovenous Fistula studies recruiting now, 13 (48%) set no upper age limit and 4 (15%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Arteriovenous Fistula with a site in France, or all of them as a file.
02

Study summary

End-stage renal disease (ESRD) is a condition in which the filtration function of the kidneys has deteriorated, necessitating dialysis or transplantation. With an aging population, the number of patients undergoing dialysis for CKD is constantly increasing.

There are different types of dialysis treatment: hemodialysis and peritoneal dialysis.

Hemodialysis involves exchanges between blood and a dialysate (a liquid used to purify blood) via a dialyzer (artificial filter), coordinated by a generator. This method requires a vascular approach, of which there are 3 types: the arteriovenous fistula (AVF), the arteriovenous graft and the central venous catheter.

The AVF remains the vascular access of choice for hemodialysis sessions, and its preservation is an essential objective for patients with CKD.

One of the major challenges for AVFs is to achieve a successful puncture, an act performed around 310 times a year per patient, for dialysis performed three times a week with double needles. This repeated procedure can cause damage to the AVF, leading to complications such as stenosis, thrombosis, aneurysm, superficial infection, hematoma, bleeding, parietal rupture or dissection.

However, there is no official recommendation on the most conservative puncture technique for AVF. In view of the number of patients concerned and the recurrence of puncture, it would seem essential to evaluate the impact of bevel orientation on the occurrence of complications during dialysis by means of a randomized prospective study.

03

Conditions studied

  • End-Stage Renal Disease Requiring Haemodialysis

Browse trials for

Keywords

  • arteriovenous fistula
  • puncture technique
  • vascular approach
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • male or female with Chronic Kidney Disease
  • patient requiring 4-hour hemodialysis sessions, 3 times per week, in a dialysis center
  • Native arteriovenous fistula (AVF) (without prosthesis), mature, with no prior puncture, located in the upper limb
  • First fistula for a hemodialysis patient
  • Expected duration of dialysis ≥ 1 year
  • Double-needle dialysis
  • Hemodialysis possible on AVF
  • Average AVF flow rate between 500 and 2,000 mL/min
  • Affiliated with a social security scheme
  • Free and

Exclusion criteria

Exclusion Criteria:

  • Auto-dialysis at home
  • Puncture using the buttonhole technique
  • Patient requiring AVF puncture with a catheter
  • Planned transplant within the next 12 months
  • Previous AVF creation, except for the fistula of interest
  • Patient with a history of cancer within the past 5 years or active cancer
  • Patient under court protection or guardianship
  • Pregnant and breast-feeding women
  • Patient with psychiatric pathologies or cognitive disorders
  • Patient follow-up difficult or impossible for geographical or other reasons, at the investigator's discretion
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
240 participants (estimated)

Study arms

  • Active comparator
    Bevel-up group

    AVF puncture will be performed with the needle bevel facing up for the entire duration of the patient's participation.

    Procedure: Needle bevel orientation for arteriovenous fistula puncture

  • Experimental
    Bevel-down group

    AVF puncture will be performed with the needle bevel facing down for the entire duration of the patient's participation

    Procedure: Needle bevel orientation for arteriovenous fistula puncture

Interventions

  • ProcedureNeedle bevel orientation for arteriovenous fistula puncture

    For the duration of the study (24 months from inclusion), the nurse will puncture the AVF according to the patient's randomization arm. Patients will be randomized, according to the minimization technique, in a 1:1 ratio between the following two groups: * Bevel-up group * Bevel-down group

06

What researchers measure

Primary outcomes

  1. Evaluate the impact of needle bevel orientation (up versus down) on the occurrence of AVF complications during dialysis sessions over 12 months in patients with ESRD

    The primary endpoint is the number of AVF complications over 12 months. Eight AVF complications will be collected (stenosis, thrombosis, aneurysm or aneurysm rupture, pseudoaneurysm, infection, hematoma, bleeding, rupture and/or parietal dissection).

    Time frame: During dialysis sessions over 12 months, from inclusion

Secondary outcomes

  1. Evaluate, in patients with CKD treated with hemodialysis, the impact of bevel orientation (up versus down) on the occurrence of AVF dysfunction requiring ultrasound during the first 24 months.

    Time from insured bipuncture to onset of AVF dysfunction (see complications in primary endpoint) requiring ultrasound over 24 months will be calculated.

    Time frame: For 24 months from inclusion

  2. Evaluate, in patients with CKD treated with hemodialysis, the impact of bevel orientation (up versus down) on the occurrence of an intervention (surgical or radiointerventional) during the first 24 months

    Time from insured bipuncture to onset of AVF dysfunction (see complications in primary endpoint) requiring initial intervention (surgical or radio-interventional) over 24 months will be calculated.

    Time frame: For 24 months from inclusion

  3. Evaluate, in patients with CKD treated with hemodialysis, the impact of bevel orientation (up versus down) on AVF survival.

    The time between the insured bipuncture and the discontinuation of its use over 24 months by the introduction of hemodialysis sessions via a central venous catheter or another AVF will be calculated

    Time frame: For 24 months from inclusion

  4. Evaluate, in patients with CKD treated with hemodialysis, the impact of bevel orientation (up versus down) on patient discomfort with fistula pain during and between dialysis sessions over 12 months

    Patient discomfort score for AVF pain during and between dialysis sessions, assessed using a simple verbal scale with a score ranging from 0 (pain free) to 4 (unbearable pain), at each session over 12 months

    Time frame: For 12 months from inclusion

  5. Evaluate, in patients with CKD treated with hemodialysis, the impact of bevel orientation (up versus down) on AVF wall thickening at the puncture site at 6, 12 and 24 months.

    Thickening of the AVF wall at the puncture site will be measured in mm by echo-Doppler at 6, 12 and 24 months.

    Time frame: At 6, 12 and 24 months from inclusion

  6. Evaluate caregivers' feedback on the two puncture techniques and any changes in their practice in terms of AVF monitoring.

    Feedback from caregivers will be evaluated via a qualitative questionnaire completed every 12 months starting from the fourth patient inclusion in each center. This aims to assess their experience with the two puncture techniques and any impact on their clinical practice.

    Time frame: At Month 12 (if at least 4 patients have been included in the center)

07

Study locations

1 of 4 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Jun 2028, 29 months after the start.

Of 58 non-industry interventional studies with no phase under Arteriovenous Fistula, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 43. This study's planned 29 months is above that.

Counting every sponsor, half of 84 studies reached it within 21 months; a quarter within 8 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 25, 2024
First posted
Nov 27, 2024
StartActual
Jan 7, 2026
Primary completionEst.
Jun 30, 2028
CompletionEst.
Jun 30, 2029
Last update
Aug 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06708338
Lead sponsor
Centre Hospitalier Emile Roux
Responsible party
Sponsor
First posted
Nov 27, 2024
Start date
Jan 7, 2026
Primary completion
Jun 30, 2028 (estimated)
Completion
Jun 30, 2029 (estimated)
Last update
Aug 4, 2026

Study contacts

David SOULIER
Contact
david.soulier@ch-lepuy.fr
0471043875
Camille FARCY
Contact
favori@ch-lepuy.fr

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion